Amylyx Pharmaceuticals, Inc. (AMLX) Income Statement
AMLX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsAMLX revenue and net income
AMLX profit margins
AMLX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −100.0% | — | — | — |
| Gross profit | −101.2% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
AMLX quarterly EPS vs estimates
Amylyx Pharmaceuticals beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.38).
AMLX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $87.4M | $380.8M | $22.2M | $285,000 | $650,000 | $1.4M |
| Cost of revenue | $525,000 | $42.2M | $25.4M | $3.0M | $52,000 | $24.6M | $11.9M |
| Gross profit | −$525,000 | $45.2M | $355.3M | $19.2M | $285,000 | −$23.9M | −$10.5M |
| Research & development | $90.4M | $104.1M | $128.2M | $93.5M | $44.0M | $24.6M | $11.9M |
| Sales, general & admin | $62.9M | $114.3M | $188.4M | $131.5M | $38.9M | $14.9M | $3.1M |
| Total operating expenses | $152.8M | $359.9M | $316.5M | $220.6M | $82.7M | $15.1M | $13.6M |
| Operating income | −$153.3M | −$314.7M | $38.8M | −$201.3M | −$82.7M | −$39.0M | −$13.6M |
| Interest income | $9.3M | $13.8M | $16.2M | $4.3M | $36,000 | $14,000 | $176,000 |
| Interest expense | — | — | — | $4.3M | $36,000 | $2.3M | $1.3M |
| Income before taxes | −$144.7M | −$302.1M | $54.3M | −$197.6M | −$87.9M | −$42.3M | −$13.7M |
| Income taxes | $46,000 | −$393,000 | $5.0M | $774,000 | −$52,000 | $2.6M | $1.1M |
| Net income | −$144.7M | −$301.7M | $49.3M | −$198.4M | −$87.9M | −$42.3M | −$14.8M |
| EBITDA | −$144.2M | −$291.0M | $55.4M | −$200.9M | −$82.6M | −$39.0M | $1.1M |
| EPS (diluted) | −$1.55 | −$2.36 | $0.70 | −$3.43 | −$7.96 | −$0.92 | — |
| Gross margin | — | 51.8% | 93.3% | 86.5% | 100.0% | −3,683.7% | −734.4% |
| Operating margin | — | −360.2% | 10.2% | −905.7% | −29,013.3% | −6,000.8% | −950.5% |
| Net margin | — | −345.4% | 12.9% | −892.4% | −30,834.7% | −6,504.6% | −1,039.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $416,000 | $0 | $88.6M | $108.4M | $102.7M |
| Cost of revenue | — | $98,000 | $108,000 | $19.9M | $141,000 | $22.1M | $160,000 | $809,000 | $7.6M | $116.4M | $9.4M | $5.2M |
| Gross profit | — | −$98,000 | −$108,000 | −$19.9M | −$141,000 | −$22.1M | −$665,000 | −$393,000 | −$8.6M | −$27.8M | $99.1M | $97.5M |
| Research & development | $23.8M | $27.6M | $21.1M | $19.9M | $27.1M | $22.1M | $22.9M | $21.2M | $23.1M | $36.6M | $44.9M | $30.0M |
| Sales, general & admin | $21.9M | $16.2M | $15.4M | $16.2M | $15.6M | $15.7M | $17.1M | $17.8M | $21.6M | $57.8M | $52.2M | $48.7M |
| Total operating expenses | $45.7M | $43.8M | $36.5M | $16.2M | $42.7M | $15.7M | $40.0M | $75.3M | $44.8M | $94.4M | $97.2M | $78.8M |
| Operating income | −$45.7M | −$43.8M | −$36.6M | −$36.0M | −$42.9M | −$37.8M | −$40.7M | −$75.7M | −$53.4M | −$122.1M | $1.9M | $18.7M |
| Interest income | $2.3M | $2.6M | $3.3M | $1.8M | $2.0M | $2.2M | $2.3M | $3.1M | $4.1M | $4.3M | $4.4M | $4.2M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $3.5M | — |
| Income before taxes | −$43.4M | −$41.3M | −$33.0M | −$34.4M | −$41.4M | −$35.9M | −$38.2M | −$72.7M | −$72.7M | −$118.6M | $6.5M | $22.4M |
| Income taxes | — | — | $46,000 | — | — | — | −$635,000 | −$72.7M | — | $242,000 | $1.7M | $1.5M |
| Net income | −$43.4M | −$41.3M | −$33.0M | −$34.4M | −$41.4M | −$35.9M | −$37.5M | −$72.7M | −$72.7M | −$118.8M | $4.7M | $20.9M |
| EBITDA | −$43.4M | −$41.2M | −$30.9M | −$34.3M | −$41.3M | −$35.8M | −$38.0M | −$72.5M | −$72.5M | −$118.2M | $6.8M | $22.7M |
| EPS (diluted) | −$0.39 | −$0.37 | −$0.30 | −$0.37 | −$0.46 | −$0.42 | −$0.55 | −$1.07 | −$0.62 | −$0.12 | $0.07 | $0.30 |
| Gross margin | — | — | — | — | — | — | — | −94.5% | — | −31.3% | 91.4% | 94.9% |
| Operating margin | — | — | — | — | — | — | — | −18,187.7% | — | −137.8% | 1.8% | 18.2% |
| Net margin | — | — | — | — | — | — | — | −17,476.9% | — | −134.0% | 4.4% | 20.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in AMLX's financial statements (latest annual report filed March 3, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
AMLX financial results
Amylyx Pharmaceuticals reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $144.7 million. Diluted earnings per share came to −$1.55.
See the AMLX stock overview for the latest quote and news, or the AMLX chart for price history and technical indicators.
AMLX income statement FAQ
Does Amylyx Pharmaceuticals have revenue?
Amylyx Pharmaceuticals reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Amylyx Pharmaceuticals profitable?
No. Amylyx Pharmaceuticals reported a net loss of $144.7 million in fiscal 2025.
How much does Amylyx Pharmaceuticals spend on research and development?
Amylyx Pharmaceuticals spent $90.4 million on research and development in fiscal 2025.
What are Amylyx Pharmaceuticals's earnings per share?
Amylyx Pharmaceuticals earned $-1.55 per diluted share in fiscal 2025, compared with $-2.36 a year earlier.
When will Amylyx Pharmaceuticals report its next earnings?
Amylyx Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens.
When does Amylyx Pharmaceuticals's fiscal year end?
Amylyx Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 3, 2026.